APGE vs HSIC
Apogee Therapeutics, Inc. vs Henry Schein — AI-powered side-by-side comparison
APGE
Apogee Therapeutics, Inc.
63
Buy
VS
| Metric | APGE | HSIC |
|---|
| AI Score |
63
|
67
|
| Price |
$134.70
|
$89.16
|
| P/E Ratio |
-31.03×
|
25.77×
|
| ROE |
-28.3%
|
12.3%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
0.0%
|
30.3%
|
| Debt / Equity |
0.01×
|
1.21×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
75.4
|
59.4
|
| Beta |
0.325
|
0.808
|
| Expected Upside |
—
|
+0.8%
|
AI Committee View
Current Innellis committee reasoning for APGE versus HSIC.
HSIC leads by 4 points.
HSIC scores 67/100 (Buy) versus APGE at 63/100 (Buy).
APGE Committee View
60% agreement
5 analysts
Positive signals support the current rating — vix regime is low -- calm backdrop supports risk-taking. The committee sees sufficient evidence to maintain the constructive view.
Bull Case
- Price structure making higher highs and higher lows — Technical
- Weekly trend (uptrend) confirms the daily trend -- multi-timeframe agreement — Technical
- Low leverage (debt-to-equity 0.00) -- balance sheet can absorb a shock — Risk
Bear Case
- ROE of only -32.6% -- cheap may mean cheap for a reason — Value
- RSI at 75 is in overbought territory — Technical
- MACD histogram negative -- bearish momentum — Technical
HSIC Committee View
75% agreement
4 analysts
The primary driver is vix regime is low -- calm backdrop supports risk-taking. The main limiting factor is growth rate is decelerating quarter over quarter -- the trend line matters more than the level. The committee is constructive but not yet at full conviction.
Bull Case
- 4 consecutive earnings beats -- consistent execution — Growth
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
Bear Case
- Growth rate is decelerating quarter over quarter -- the trend line matters more than the level — Growth